167 related articles for article (PubMed ID: 29100868)
21. Infection Dynamics of Aspergillus fumigatus in Adults with Cystic Fibrosis (CF).
Moore JE; Rendall JC; Millar BC
Mycopathologia; 2023 Oct; 188(5):699-704. PubMed ID: 37012557
[TBL] [Abstract][Full Text] [Related]
22. Impact of MIF gene promoter polymorphism on F508del cystic fibrosis patients.
Melotti P; Mafficini A; Lebecque P; Ortombina M; Leal T; Pintani E; Pepermans X; Sorio C; Assael BM
PLoS One; 2014; 9(12):e114274. PubMed ID: 25503271
[TBL] [Abstract][Full Text] [Related]
23. Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR.
Taylor-Cousar JL; Jain M; Barto TL; Haddad T; Atkinson J; Tian S; Tang R; Marigowda G; Waltz D; Pilewski J;
J Cyst Fibros; 2018 Mar; 17(2):228-235. PubMed ID: 29126871
[TBL] [Abstract][Full Text] [Related]
24. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C.
Massie RJ; Poplawski N; Wilcken B; Goldblatt J; Byrnes C; Robertson C
Eur Respir J; 2001 Jun; 17(6):1195-200. PubMed ID: 11491164
[TBL] [Abstract][Full Text] [Related]
25. Immunoreactive trypsin/DNA newborn screening for cystic fibrosis: should the R117H variant be included in CFTR mutation panels?
Scotet V; Audrézet MP; Roussey M; Rault G; Dirou-Prigent A; Journel H; Moisan-Petit V; Storni V; Férec C
Pediatrics; 2006 Nov; 118(5):e1523-9. PubMed ID: 17015492
[TBL] [Abstract][Full Text] [Related]
26. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.
Rowe SM; McColley SA; Rietschel E; Li X; Bell SC; Konstan MW; Marigowda G; Waltz D; Boyle MP;
Ann Am Thorac Soc; 2017 Feb; 14(2):213-219. PubMed ID: 27898234
[TBL] [Abstract][Full Text] [Related]
27. Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T.
Carter S; Kelly S; Caples E; Grogan B; Doyle J; Gallagher CG; McKone EF
J Cyst Fibros; 2015 Jul; 14(4):e4-5. PubMed ID: 25698453
[TBL] [Abstract][Full Text] [Related]
28. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.
Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET
Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367
[TBL] [Abstract][Full Text] [Related]
29. [Cystic fibrosis in a woman aged seventy].
Ras JE; van Velzen E; van Berkhout FT; van den Brand JJ
Ned Tijdschr Geneeskd; 2010; 154():A1342. PubMed ID: 20619026
[TBL] [Abstract][Full Text] [Related]
30. Early childhood lung function is a stronger predictor of adolescent lung function in cystic fibrosis than early Pseudomonas aeruginosa infection.
Pittman JE; Noah H; Calloway HE; Davis SD; Leigh MW; Drumm M; Sagel SD; Accurso FJ; Knowles MR; Sontag MK
PLoS One; 2017; 12(5):e0177215. PubMed ID: 28505188
[TBL] [Abstract][Full Text] [Related]
31. Pulmonary function disparities exist and persist in Hispanic patients with cystic fibrosis: A longitudinal analysis.
McGarry ME; Neuhaus JM; Nielson DW; Burchard E; Ly NP
Pediatr Pulmonol; 2017 Dec; 52(12):1550-1557. PubMed ID: 29082671
[TBL] [Abstract][Full Text] [Related]
32. The relationship between sweat chloride levels and mortality in cystic fibrosis varies by individual genotype.
Espel JC; Palac HL; Bharat A; Cullina J; Prickett M; Sala M; McColley SA; Jain M
J Cyst Fibros; 2018 Jan; 17(1):34-42. PubMed ID: 29221674
[TBL] [Abstract][Full Text] [Related]
33. Risk factors for lung function decline in a large cohort of young cystic fibrosis patients.
Cogen J; Emerson J; Sanders DB; Ren C; Schechter MS; Gibson RL; Morgan W; Rosenfeld M;
Pediatr Pulmonol; 2015 Aug; 50(8):763-70. PubMed ID: 26061914
[TBL] [Abstract][Full Text] [Related]
34. Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosis.
Wagener JS; Williams MJ; Millar SJ; Morgan WJ; Pasta DJ; Konstan MW
J Cyst Fibros; 2018 Jul; 17(4):496-502. PubMed ID: 29685810
[TBL] [Abstract][Full Text] [Related]
35. The novel complex allele [A238V;F508del] of the CFTR gene: clinical phenotype and possible implications for cystic fibrosis etiological therapies.
Diana A; Polizzi AM; Santostasi T; Ratclif L; Pantaleo MG; Leonetti G; Iusco DR; Gallo C; Conese M; Manca A
J Hum Genet; 2016 Jun; 61(6):473-81. PubMed ID: 26911355
[TBL] [Abstract][Full Text] [Related]
36. Negative sweat test in hypertrypsinaemic infants with cystic fibrosis carrying rare CFTR mutations.
Padoan R; Bassotti A; Seia M; Corbetta C
Eur J Pediatr; 2002 Apr; 161(4):212-5. PubMed ID: 12014388
[TBL] [Abstract][Full Text] [Related]
37. Assessment of CFTR function in homozygous R117H-7T subjects.
de Nooijer RA; Nobel JM; Arets HG; Bot AG; van Berkhout FT; de Rijke YB; de Jonge HR; Bronsveld I
J Cyst Fibros; 2011 Sep; 10(5):326-32. PubMed ID: 21507732
[TBL] [Abstract][Full Text] [Related]
38. Gaps in Cystic Fibrosis Care Are Associated with Reduced Lung Function in the U.S. Cystic Fibrosis Foundation Patient Registry.
Sears EH; Hinton AC; Lopez-Pintado S; Lary CW; Zuckerman JB
Ann Am Thorac Soc; 2023 Sep; 20(9):1250-1257. PubMed ID: 37027571
[No Abstract] [Full Text] [Related]
39. [Italian Cystic Fibrosis Registry (ICFR). Report 2015-2016].
Giordani B; Amato A; Majo F; Ferrari G; Quattrucci S; Minicucci L; Padoan R; Floridia G; Salvatore D; Carnovale V; Puppo Fornaro G; Taruscio D; Salvatore M;
Epidemiol Prev; 2019; 43(4S1):1-36. PubMed ID: 31370382
[TBL] [Abstract][Full Text] [Related]
40. Delayed diagnosis of cystic fibrosis associated with R117H on a background of 7T polythymidine tract at intron 8.
Peckham D; Conway SP; Morton A; Jones A; Webb K
J Cyst Fibros; 2006 Jan; 5(1):63-5. PubMed ID: 16266832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
